Tiziana Reports Positive Preclinical Data for Foralumab in Long COVID

Tiziana Life Sciences announced positive preclinical data for its intranasal foralumab in a Long COVID mouse model. The study, published in bioRxiv, showed that nasal anti-CD3 treatment significantly reduced neuroinflammation, boosted regulatory T cells in the brain, restored hippocampal neurogenesis, and improved short-term memory. These findings suggest a promising, non-invasive strategy to address cognitive impairment in Long COVID patients and support the broad therapeutic potential of foralumab.